This trial is an open-label, multicenter phase Ib/II clinical study to evaluate the efficacy and safety of LBL-024 monotherapy or in combination with albumin-bound paclitaxel in patients with recurrent or metastatic triple negative breast cancer(TNBC).
Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.
At the time of signing the informed consent form, the age was ≥ 18 years old.
The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0~1.
The expected survival time is at least 12 weeks.
Use of immunomodulatory drugs within 2 weeks prior to first dose of study drug.
Patients who received live vaccination within 4 weeks before the first dose of study drug or who are scheduled to receive live vaccination during the study treatment period and within 4 weeks after the last dose.
Patients with clinically uncontrolled pleural effusion, peritoneal effusion, or pericardial effusion.
Active infection within 2 weeks prior to first dose of study drug.
Nanjing Leads Biolabs Co.,Ltd
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Collaborator